Alector, Inc. (ALEC)
NASDAQ: ALEC · Real-Time Price · USD
2.180
+0.180 (9.00%)
At close: Aug 13, 2025, 4:00 PM
2.170
-0.010 (-0.46%)
Pre-market: Aug 14, 2025, 8:57 AM EDT
Alector Revenue
Alector had revenue of $7.87M in the quarter ending June 30, 2025, a decrease of -47.80%. This brings the company's revenue in the last twelve months to $81.13M, up 46.78% year-over-year. In the year 2024, Alector had annual revenue of $100.56M with 3.60% growth.
Revenue (ttm)
$81.13M
Revenue Growth
+46.78%
P/S Ratio
2.66
Revenue / Employee
$340,882
Employees
238
Market Cap
220.64M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 100.56M | 3.50M | 3.60% |
Dec 31, 2023 | 97.06M | -36.56M | -27.36% |
Dec 31, 2022 | 133.62M | -73.47M | -35.48% |
Dec 31, 2021 | 207.09M | 185.99M | 881.54% |
Dec 31, 2020 | 21.10M | -121.00K | -0.57% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ALEC News
- 5 days ago - Alector, Inc. (ALEC) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Alector Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 13 days ago - Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call - GlobeNewsWire
- 2 months ago - Alector Provides Executive Leadership Update - GlobeNewsWire
- 2 months ago - Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 3 months ago - Alector Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Alector to Participate in Upcoming Healthcare Conferences - GlobeNewsWire
- 4 months ago - Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease - GlobeNewsWire